TVTX Q2 2024 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$54M+68.1% YoY

Gross Profit

$42M77.1% margin

Operating Income

-$67M-123.9% margin

Net Income

-$70M-130.1% margin

EPS (Diluted)

$-0.91

QoQ Revenue Growth

+30.8%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$52M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$551M

Total Liabilities

$536M

Stockholders' Equity

$15M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$54M	$32M	+68.1%
Gross Profit	$42M	$31M	+35.7%
Operating Income	-$67M	-$104M	+35.5%
Net Income	-$70M	-$86M	+17.8%

Revenue Segments

Product

$52M96%

License

$2M4%